1 December 2025 | Lomé, Togo
As the world marks World AIDS Day 2025, the World Health Organization (WHO) is calling for urgent global action to expand access to innovative HIV prevention tools—particularly lenacapavir (LEN)—while strengthening essential health services disrupted by recent cuts in international funding.
Despite financial setbacks, 2025 has seen encouraging progress with the introduction and WHO approval of twice-yearly injectable lenacapavir, a long-acting HIV prevention option designed to overcome challenges of daily pill adherence and stigma. This breakthrough is poised to significantly shift HIV prevention efforts across Africa.
A Critical Moment for Africa’s HIV Response
WHO warns that sharp reductions in donor funding during 2025 have disrupted HIV prevention, testing, and treatment services. Community-led programmes—especially PrEP services and harm-reduction initiatives—have been scaled back or halted in several countries.
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, emphasized:
“We face significant challenges, with cuts to international funding and prevention stalling. At the same time, we have significant opportunities, with exciting new tools with the potential to change the trajectory of the HIV epidemic.”
UNAIDS data from 2024 highlight the urgency:
- 1.3 million new HIV infections recorded globally
- 49% of new infections occurred among key populations and their partners
- Key population risk levels remain extremely high:
- Sex workers: 17× higher risk
- Transgender women: 17× higher risk
- Men who have sex with men: 18× higher risk
- People who inject drugs: 34× higher risk
- 40.8 million people living with HIV globally
- 630,000 AIDS-related deaths
Further, an estimated 2.5 million PrEP users lost access to medication in 2025 due to donor funding cuts—threatening progress toward ending AIDS by 2030.
A New Era of HIV Prevention: Lenacapavir (LEN)
Lenacapavir represents one of the most significant innovations in HIV prevention. WHO prequalified LEN on 6 October 2025, enabling rapid adoption in African countries. National regulatory approvals soon followed in:
- South Africa – 27 October 2025
- Zimbabwe – 27 November 2025
- Zambia – 4 November 2025
Supported by WHO’s Collaborative Registration Procedure (CRP), these approvals will speed up access to this long-acting injectable for populations most at risk.
InTraHealth’s Commitment to Strengthening HIV Prevention and Care
As a specialised Healthcare and Medical Technology Unit headquartered in Lomé, Togo, InTraHealth is committed to supporting Africa’s public health systems through:
Integrated HIV screening & diagnostics solutions
Including rapid test kits, laboratory systems, and digital reporting tools.
Access to innovative HIV prevention technologies
Supporting health facilities and ministries to adopt WHO-approved solutions such as long-acting PrEP options.
Strengthening supply chains and last-mile delivery
Ensuring life-saving commodities reliably reach rural and high-risk communities.
Digital health & telemedicine platforms
Improving patient follow-up, adherence monitoring, and access to care.
Capacity building for healthcare professionals
With training programs spanning HIV prevention, counselling, diagnostics and treatment monitoring.
Regional presence and partnerships
Headquarted in Lome , Togo with operational offices in Cote d’Ivoire and Ghana, InTraHealth Solutions collaborates with governments, NGOs, and l health agencies to improve health outcomes across West & Central Africa.
Driving Africa’s Response Forward
Under the World AIDS Day theme “Overcoming disruption, transforming the AIDS response”, the call to action is clear:
Africa must combine solidarity, innovation, and investment to protect vulnerable communities and accelerate progress toward ending AIDS.
InTraHealth remains committed to leveraging technology, partnerships, and community-centred solutions to support this mission and ensure that transformative tools like lenacapavir reach the populations most in need.
Contact InTraHealth Solutions (Powered by InTraDev)
Headquarters – Togo
Location: Lomé, Togo
Phone: +228 92 68 51 79
Email: info.healthcare@intradevafrica.com
Ghana Office
Location: Accra, Ghana
Phone: +233 277 672981
Email: info.healthcare@intradevafrica.com
Website
Follow Us
LinkedIn | Facebook | X (Twitter)